• Explore /
  • Poster
  • / Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN

Johanna C. Bendell , John D. Powderly II, Christopher Hanyoung Lieu , S. Gail Eckhardt , Herbert Hurwitz , Howard S. Hochster , Janet E. Murphy , Roel Peter Funke , Cheryl Rossi , Jeffrey Wallin , Daniel Waterkamp , Michael J. Pishvaian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01633970

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 704)

DOI

10.1200/jco.2015.33.3_suppl.704

Abstract #

704

Poster Bd #

D46

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma.

Phase I trial of perioperative chemotherapy plus immunotherapy in localized esophageal and gastroesophageal adenocarcinoma.

First Author: Mariela A. Blum Murphy

First Author: Jiwon Lee

First Author: Patricio Eduardo Yanez

First Author: Vassiliki Papadimitrakopoulou